Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul:187:104035.
doi: 10.1016/j.critrevonc.2023.104035. Epub 2023 May 26.

The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

Affiliations
Review

The 2022 Assisi Think Tank Meeting: White paper on optimising radiation therapy for breast cancer

C Aristei et al. Crit Rev Oncol Hematol. 2023 Jul.

Abstract

The present white paper, referring to the 4th Assisi Think Tank Meeting on breast cancer, reviews state-of-the-art data, on-going studies and research proposals. <70% agreement in an online questionnaire identified the following clinical challenges: 1: Nodal RT in patients who have a) 1-2 positive sentinel nodes without ALND (axillary lymph node dissection); b) cN1 disease transformed into ypN0 by primary systemic therapy and c) 1-3 positive nodes after mastectomy and ALND. 2. The optimal combination of RT and immunotherapy (IT), patient selection, IT-RT timing, and RT optimal dose, fractionation and target volume. Most experts agreed that RT- IT combination does not enhance toxicity. 3: Re-irradiation for local relapse converged on the use of partial breast irradiation after second breast conserving surgery. Hyperthermia aroused support but is not widely available. Further studies are required to finetune best practice, especially given the increasing use of re-irradiation.

Keywords: Breast cancer; Combined modality treatment; Immunotherapy; Radiation therapy; Re-irradiation in relapsed patients.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest On behalf of my co-authors (O. Kaidar-Person, L. Boersma, M. C. Leonardi, B. Offersen, P. Franco, M. Arenas, C. Bourgier, R. Pfeffer, V Kouloulias, Y. Bölükbaşı, I. Meattini, C. Coles, A. Montero Luis, V. Masiello, I. Palumbo, A. Morganti, E. Perrucci, V. Tombolini, M. Krengli, F. Marazzi, L. Trigo, S. Borghesi, A. Ciabattoni, I. Ratoša, V. Valentini, P. Poortmans) I declare there is no conflict of interest in this study and that no funding was received from any source.

LinkOut - more resources